GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Samsung Biologics Co 207940.KS · KRW

Health Care · Life Sciences Tools & Services · KRX · 🇰🇷 South Korea

Compare

1,510,000

-0.40%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Samsung Biologics Co

Its shares trade on KRX under the ticker 207940.KS. It has been listed since 10 November 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩4.56trn and net income of ₩1.78trn. At that date it held total assets of ₩11.06trn and shareholders' equity of ₩7.45trn.

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company is headquartered in Incheon, Incheon. The company went IPO on 2016-11-10. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. The company also provides cell line development and process development services. The firm distributes its products in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
10 Nov 2016

Leadership

Pay as last reported

  • Mr. John RimPresident, Chief Executive Officer, Director₩7.91bn
  • Mr. Seung Ho YooVice President, Director, since 2023
  • Mr. Gyun NohVice President, Director, since 2021₩2.19bn
  • Diane BlackVice President
  • Mr. Pierre CatignolVice President₩1.52bn
  • Mr. James ChoiVice President, since 2021
  • Mr. Gyu Ho LeeVice President
  • Mr. Ho Seong MinVice President₩2.17bn
  • Mr. Kevin SharpVice President
  • Mr. Javier CamposanoAssistant Managing Director
  • Mr. Seong Hwan ChoAssistant Managing Director
  • Mr. Seong Yil ChoAssistant Managing Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
93
Environment
99
Social
99
Governance
80
Direct emissions (scope 1)
70,471.996 t
Energy emissions (scope 2)
155,521.967 t
Value chain emissions (scope 3)
513,803.084 t
Women in the workforce
42.96009%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Samsung Biologics Co Ltd possesses several strengths that contribute to its success:

Weaknesses

  • Despite its strengths, Samsung Biologics Co Ltd faces certain weaknesses that need to be addressed:

Opportunities

  • Samsung Biologics Co Ltd can leverage the following opportunities to expand and enhance its business:

Threats

  • Samsung Biologics Co Ltd must be aware of the following potential threats that could impact its operations:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.